On June 26th, Sihuan Pharm announced on the HKEx that its subsidiary, Honghe Pharmaceutical Co., Ltd., had developed Tokai Griloro dispersible tablets (specification: 90mg), which obtained drug registration approval issued by the National Medical Products Administration and is considered to have passed the consistency evaluation of generic drug quality and efficacy. This product, developed by Honghe Pharmaceutical, is the first domestic product to be approved for listing. Togrillo is a new type of anti-thrombotic drug with a strong anti-platelet aggregation effect to prevent thrombus formation. It is currently recommended by guidelines at home and abroad as an anti-platelet drug for thrombus prevention in patients with cardiovascular diseases. Tokai Griloro dispersible tablets belongs to the national medical insurance category B product.